Literature DB >> 22512691

Reduced circulating miR-15b is correlated with phosphate metabolism in patients with end-stage renal disease on maintenance hemodialysis.

Honglei Wang1, Wujian Peng, Xin Ouyang, Yong Dai.   

Abstract

BACKGROUND: Disorders of mineral metabolism can facilitate the progression of vascular calcification and are closely associated with adverse outcomes in end-stage renal disease (ESRD). miR-15b has been implicated in the epigenetic regulation of key metabolism, stress response, and osteoblast differentiation. METHODS AND
RESULTS: In this study, we detected miR-15b in the plasma of 30 patients with ESRD and 20 healthy controls using real-time quantitative RT-PCR (RT-qPCR). Compared with healthy controls, the circulating levels of miR-15b were significantly reduced in patients with ESRD. However, there is no significant difference in circulating miR-15b levels when comparing prehemodialysis and posthemodialysis in patients with ESRD. In addition, to further estimate the potential roles of aberrantly expressed candidate miR-15b in the pathogenesis of ESRD, we utilized a bioinformatics exploratory analysis and identified gene ontology "biological process" classifications which revealed that dysregulated circulating miR-15b might be involved in phosphate metabolism. Furthermore, circulating miR-15b positively correlated with both estimated glomerular filtration rate (r = 0.502, p = 0.003) and hemoglobin levels (r = 0.432, p = 0.017) and inversely correlated with phosphate level (r = -0.516, p = 0.004).
CONCLUSION: The findings indicated that the dysregulated miR-15b might contribute to the progression of ESRD by modulating genes that might be involved in the phosphate metabolism, which might have the potential of being used as a biomarker for monitoring disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22512691     DOI: 10.3109/0886022X.2012.676491

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  7 in total

1.  RKNNMDA: Ranking-based KNN for MiRNA-Disease Association prediction.

Authors:  Xing Chen; Qiao-Feng Wu; Gui-Ying Yan
Journal:  RNA Biol       Date:  2017-04-19       Impact factor: 4.652

Review 2.  The regulation and function of microRNAs in kidney diseases.

Authors:  Qingqing Wei; Qing-Sheng Mi; Zheng Dong
Journal:  IUBMB Life       Date:  2013-07       Impact factor: 3.885

Review 3.  MicroRNAs Regulate Vascular Medial Calcification.

Authors:  Jane A Leopold
Journal:  Cells       Date:  2014-10-14       Impact factor: 6.600

4.  Circulating MiR-133a as a biomarker predicts cardiac hypertrophy in chronic hemodialysis patients.

Authors:  Ping Wen; Dan Song; Hong Ye; Xiaochun Wu; Lei Jiang; Bing Tang; Yang Zhou; Li Fang; Hongdi Cao; Weichun He; Yafang Yang; Chunsun Dai; Junwei Yang
Journal:  PLoS One       Date:  2014-10-14       Impact factor: 3.240

5.  MicroRNAs in the miR-17 and miR-15 families are downregulated in chronic kidney disease with hypertension.

Authors:  Priyanka Nandakumar; Adrienne Tin; Megan L Grove; Jianzhong Ma; Eric Boerwinkle; Josef Coresh; Aravinda Chakravarti
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

6.  Circulating microRNAs and vascular calcification in hemodialysis patients.

Authors:  Chien-Te Lee; Yueh-Ting Lee; You-Lin Tain; Hwee-Yeong Ng; Wei-Hung Kuo
Journal:  J Int Med Res       Date:  2019-05-30       Impact factor: 1.671

Review 7.  The Epigenetic Landscape of Vascular Calcification: An Integrative Perspective.

Authors:  Yi-Chou Hou; Chien-Lin Lu; Tzu-Hang Yuan; Min-Tser Liao; Chia-Ter Chao; Kuo-Cheng Lu
Journal:  Int J Mol Sci       Date:  2020-02-01       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.